virus
two
oppos
face
one
hand
caus
harm
diseas
viru
may
manifest
directli
contagi
diseas
clinic
patholog
vari
signific
viral
infect
also
delay
consequ
rare
case
may
caus
cellular
transform
cancer
hand
virus
may
provid
hope
hope
efficaci
treatment
seriou
diseas
exampl
latter
use
virus
vaccin
transfer
vector
therapeut
gene
gene
therapi
set
directli
therapeut
anticanc
agent
oncolyticviru
therapi
set
alreadi
evid
antitumor
activ
oncolyt
virus
antitumor
efficaci
seem
link
capac
induc
tumordirect
immun
respons
provid
overview
develop
oncolyt
virus
clinic
evalu
dutch
perspect
f
rom
onward
relat
virus
host
cell
much
studi
netherland
initi
focu
biolog
bacteriophag
well
virus
higher
eukaryot
subsequ
virus
studi
model
system
cellular
process
utrecht
sussenbach
van
der
vliet
studi
fate
adenoviru
dna
host
cell
mechan
adenovirus
use
replic
dna
genom
shed
light
viral
cellular
protein
involv
adenoviru
replic
studi
identifi
role
human
transcript
factor
nfi
orchestr
initi
complex
involv
adenoviru
type
dna
replic
illustr
interplay
cellular
viral
process
involv
adenoviru
replic
review
hoeben
uil
observ
virus
could
transform
cell
intrigu
stimul
studi
obtain
insight
process
involv
cellular
transform
van
den
noordaa
amsterdam
van
der
eb
leiden
use
adenoviru
tumorinduc
agent
rodent
model
graham
van
der
eb
demonstr
human
cell
could
transform
nake
adenoviru
dna
use
calcium
phosphat
coprecipit
techniqu
effici
transfer
nake
dna
target
cell
graham
van
der
eb
subsequ
techniqu
use
studi
differ
oncogen
potenti
adenoviru
type
differ
found
correl
differenti
effect
adenoviru
protein
express
cellular
mhcclass
molecul
schrier
et
al
link
antigen
present
oncogen
subsequ
research
also
yield
cell
line
use
often
tool
researchand
clinicalgrad
product
adenoviru
vector
fallaux
et
al
radiobiolog
institut
rijswijk
bentvelzen
studi
transmiss
mous
mammari
tumor
viru
mmtv
way
mmtv
induc
breast
cancer
rodent
similar
approach
taken
bern
netherland
cancer
institut
amsterdam
analyz
murin
leukemia
virus
integr
site
identifi
cellular
gene
pathway
involv
leukemogenesi
mice
henc
oncogen
virus
associ
cancer
activ
investig
sever
dutch
group
environ
dutch
enter
gene
therapi
arena
van
der
eb
lab
valerio
pioneer
field
among
first
clone
adenosinedeaminas
gene
cdna
valerio
et
al
demonstr
retrovir
vector
could
construct
function
express
cdna
valerio
continu
research
radiobiolog
institut
rijswijk
benefit
expertis
hematopoiet
stem
cell
research
van
bekkum
facil
bone
marrow
transplant
research
monkey
follow
pioneer
work
team
led
w
french
anderson
r
michael
blaes
ken
culver
nih
first
treat
children
suffer
sever
combin
immun
defici
due
adenosin
deaminas
defici
adascid
genemodifi
autolog
cell
culver
et
al
valerio
team
focus
modif
bone
marrow
stem
cell
preclin
studi
van
beusechem
et
al
final
led
one
first
clinic
studi
retrovir
vector
use
transfer
ada
gene
hematopoiet
stem
cell
hoogerbrugg
et
al
studi
offer
hope
cure
adascid
patient
inde
applic
gene
therapi
trail
blazer
ever
sinc
date
gene
therapi
success
appli
patient
adascid
cancer
becam
promin
target
gene
therapi
research
netherland
osanto
collabor
initi
clinic
studi
involv
vaccin
allogen
tumor
cell
modifi
express
interleukin
patient
metastat
melanoma
osanto
et
al
subsequ
sever
group
develop
tumortarget
replic
nonrepl
vector
cancer
therapi
scientist
keen
develop
new
vector
also
new
system
test
safeti
efficaci
approach
preclin
test
involv
rang
differ
assay
involv
tumor
cell
grown
monolay
spheroid
cultur
addit
new
test
system
develop
mimic
tumor
faith
model
includ
tumor
cell
explant
tissu
slice
human
tumor
grown
embryon
chicken
egg
rot
et
al
durupt
et
al
recent
merit
variou
preclin
tumor
model
excel
review
de
jong
et
al
sever
replicationdefect
adenoviru
retroviru
vector
evalu
earlyphas
clinic
trial
netherland
least
four
clinic
center
particip
cancer
gene
therapi
clinic
trial
name
erasmu
medic
center
rotterdam
leiden
univers
medic
center
vu
univers
medic
center
amsterdam
univers
medic
center
groningen
studi
vector
encod
prodrugactiv
enzym
use
addit
sever
studi
focu
immunogen
therapi
approach
cancer
employ
adenoviru
canari
pox
plasmid
vector
schenkbraat
et
al
also
use
replicationcompet
virus
preferenti
infect
kill
cancer
cell
explor
cancer
treatment
virus
design
oncolyt
virus
far
adenoviru
prime
oncolyt
viru
dutch
preclin
research
viral
anticanc
agent
main
theme
dutch
research
adenoviru
vector
develop
direct
tumor
target
transcript
target
glioma
could
achiev
inclus
promot
specif
express
glial
glioma
cell
de
leeuw
et
al
amsterdam
bosma
group
target
gastrointestin
tumor
wessel
et
al
sever
approach
capsid
modif
use
bispecif
antibodi
target
adapt
molecul
first
evalu
replicationdefect
gene
transfer
vector
van
beusechem
et
al
beusechem
et
al
vellinga
et
al
brouwer
et
al
schagen
et
al
kuhlmann
et
al
de
vrij
et
al
later
implement
oncolyt
adenovirus
van
beusechem
et
al
carett
et
al
sebestyen
et
al
transcript
target
oncolyt
adenoviru
recent
undergon
extens
preclin
safeti
assess
current
evalu
investigatordriven
clinic
trial
rotterdam
schenk
et
al
addit
success
tropism
modif
develop
abroad
adopt
incorpor
integrinbind
rgd
motif
adenoviru
fiber
use
fiberswitch
mutant
use
affibodi
molecul
target
ligand
witlox
et
al
magnusson
et
al
second
focu
dutch
oncolyt
adenoviru
research
augment
lytic
replic
cancer
cell
spread
solid
tumor
exampl
includ
tumor
suppressor
protein
promot
adenovirusinduc
cell
death
result
acceler
progeni
viru
releas
effect
tumor
erad
van
beusechem
et
al
geoerger
et
al
heideman
et
al
carboxylesteras
prodrugconvert
enzym
effect
combin
oncolyt
adenoviru
plu
enzym
prodrug
therapi
oosterhoff
et
al
proapoptot
antiangiogen
tissu
inhibitor
lamfer
et
al
vector
design
target
varieti
cancer
type
involv
major
cancer
type
evalu
relev
preclin
model
recent
dutch
biotechnolog
compani
orca
therapeut
construct
oncolyt
adenoviru
incorpor
gainoffunct
mutat
identifi
alemani
colleagu
spain
gro
et
al
mutat
reloc
protein
plasma
membran
induc
membran
permeabil
enhanc
viru
releas
viru
current
develop
clinic
test
prostat
cancer
addit
dutch
research
develop
technolog
exploit
rna
interfer
context
replic
oncolyt
adenoviru
carett
et
al
short
hairpin
express
genom
oncolyt
adenoviru
replic
human
cancer
cell
properli
process
cellular
rnai
machineri
select
silenc
target
gene
henc
becam
possibl
express
exogen
transgen
strengthen
oncolyt
viru
replic
also
silenc
endogen
host
gene
express
might
inhibit
effect
oncolyt
adenoviru
replic
open
new
possibl
improv
oncolyt
viru
design
oncolyt
adenoviru
rnai
also
use
modul
immun
respons
tumor
microenviron
see
high
medic
need
treat
advanc
cancer
therefor
viru
deliveri
method
sought
allow
system
administr
reach
tumor
metastas
intravascular
deliveri
adenoviru
vector
hamper
effect
sequestr
liver
interact
blood
cell
plasma
protein
effect
recognit
host
innat
immun
system
review
hendrickx
et
al
effect
wide
recogn
confound
effect
therapi
direct
research
adenoviru
vector
engin
contribut
dutch
research
area
includ
exploit
natur
divers
adenoviru
serotyp
construct
adenoviru
vector
bypass
preexist
immun
vogel
et
al
holterman
et
al
evalu
capsid
modif
abolish
interact
natur
receptor
van
beusechem
et
al
schagen
et
al
schagen
et
al
present
adenoviru
vector
lack
bind
site
nativ
receptor
bloodclot
factor
complement
compon
capsid
consequ
vector
exhibit
diminish
capac
bind
human
erythrocyt
strongli
reduc
hepat
tropism
improv
bioavail
upon
system
deliveri
mice
schagen
et
al
also
physic
coat
adenoviru
particl
shown
contribut
system
anticanc
efficaci
accept
toxic
least
anim
model
morrison
et
al
doronin
et
al
interestingli
mutant
adenovirus
obtain
bioselect
display
improv
system
antitumor
efficaci
kuhn
et
al
increas
blood
persist
enhanc
antitumor
efficaci
gro
et
al
bioselect
facilit
use
errorpron
adenoviru
dna
polymeras
mutant
gener
genet
divers
uil
et
al
use
mutant
enhanc
spontan
mutat
rate
adenoviru
replic
two
order
magnitud
evolut
bioselect
replic
adenovirus
human
ovarium
carcinoma
cell
yield
virus
mutat
splice
acceptor
site
preced
open
read
frame
encod
adenoviru
death
protein
adp
mutat
result
prematur
express
adp
acceler
tumor
cell
lysi
uil
et
al
interest
develop
use
cellular
carrier
transport
oncolyt
virus
bloodstream
toward
tumor
nakashima
et
al
way
viru
may
protect
clearanc
immun
system
sequestr
nontarget
tissu
promis
cell
type
purpos
mesenchym
stem
cell
msc
abil
home
toward
tumor
oncolyt
adenovirus
success
deliv
orthotop
breast
lung
tumor
follow
intraven
administr
hakkarainen
et
al
orthotop
brain
tumor
follow
carotid
arteri
inject
yong
et
al
intriguingli
adenoviru
infect
found
compromis
home
capac
adipos
tissuederiv
stem
cell
mice
bear
orthotop
human
glioma
xenograft
mechan
respons
observ
inhibit
remain
elucid
furthermor
known
whether
cargo
viru
replic
compet
msc
msc
mere
hand
viru
particl
expos
interest
approach
use
pharmaceut
induct
oncolyt
viru
releas
msc
infiltr
tumor
hsiao
et
al
anoth
carrier
system
studi
balver
et
al
demonstr
potenti
employ
tcellderiv
jurkat
cell
deliv
oncolyt
adenoviru
core
infiltr
zone
intracrani
glioma
mice
therebi
open
prospect
futur
autolog
tcellmedi
oncolyt
viru
deliveri
although
clear
advanc
made
toward
oncolyt
adenovirus
use
system
clinic
implement
system
cancer
treatment
oncolyt
virus
yet
consid
netherland
dutch
ongo
plan
clinic
trial
oncolyt
virus
treat
local
recurr
prostat
cancer
glioblastoma
multiform
latter
case
viru
administ
convectionenhanc
deliveri
ced
local
enhanc
vector
distribut
method
viru
slowli
infus
via
cathet
implant
brain
thu
bypass
bloodbrain
barrier
rat
model
idema
et
al
demonstr
distribut
adenoviru
particl
deliv
via
ced
least
partial
volum
depend
viru
infus
white
matter
tract
gray
matter
distant
tumor
could
reach
penetr
tumor
limit
idema
et
al
therefor
ced
method
seem
particularli
use
deliveri
oncolyt
adenovirus
infiltr
brain
tumor
cancer
cell
migrat
surround
brain
parenchyma
variou
group
evalu
replicationcompet
adenoviru
vector
preclin
studi
far
two
replic
oncolyt
virus
reach
stage
clinic
evalu
netherland
rotterdamamsterdam
collabor
studi
expandedtrop
tumorselect
adenoviru
evalu
treatment
glioblastoma
far
approxim
patient
enrol
phase
iii
studi
administr
viru
ced
found
safe
interrupt
phase
dose
escal
patient
safeti
issu
c
dirven
rotterdam
netherland
person
commun
addit
bangma
group
rotterdam
studi
safeti
condit
replic
adenoviru
vector
ad
phase
dose
escal
trial
patient
local
prostat
cancer
schedul
cur
radic
prostatectomi
far
data
publish
either
clinic
studi
studi
benefit
dedic
grant
support
zonmw
translat
gene
therapi
research
program
subsid
dutch
health
ministri
parallel
virus
exploit
preclin
studi
van
den
hoogen
explor
unmodifi
newcastl
diseas
viru
ndv
oncolyt
agent
panel
human
pancreat
carcinoma
cell
line
order
assess
heterogen
properti
human
pancreat
carcinoma
buij
et
al
gerritsen
rottier
lab
experi
target
nonhuman
coronavirus
human
tumor
cell
use
bispecif
singlechain
antibodi
wurding
et
al
along
line
group
redirect
coronaviru
murin
hepat
viru
mhv
normal
unabl
infect
human
cell
human
tumor
cell
via
solubl
receptor
fuse
epiderm
growth
factor
receptor
egfr
target
moieti
inclus
mhv
genom
express
cassett
encod
fusion
protein
allow
infect
egfrexpress
tumor
cell
administr
viru
mice
bear
lethal
intracrani
egfrexpress
glioma
could
prolong
surviv
treat
mice
compar
mockinfect
control
virusinfect
mice
verheij
et
al
kranenburg
exploit
reoviru
studi
mechan
reoviru
prefer
lyse
tumor
cell
rather
normal
nontransform
cell
smakman
et
al
studi
provid
evid
ra
signal
tumor
cell
may
facilit
reoviru
infect
variou
level
stimul
reoviru
entri
stimul
viru
uncoat
reoviru
gene
express
genom
replic
reoviru
egress
develop
reovirus
oncolyt
agent
hoeben
lab
use
genet
modif
bioselect
spontan
mutant
obtain
reovirus
amend
tropism
genet
target
virus
gener
could
use
artifici
receptor
cell
lack
express
canon
reoviru
receptor
jama
cell
surfac
van
den
wollenberg
et
al
bioselect
approach
yield
tropismand
hostrangeexpand
reovirus
capabl
infect
cell
independ
jama
purportedli
via
interact
via
sialic
acid
van
den
wollenberg
et
al
virus
may
use
oncolyt
agent
tumor
express
jama
cell
surfac
although
promis
remain
establish
import
jama
express
wildtyp
reoviru
infect
tumor
cell
vivo
recent
demonstr
reovirus
recruit
altern
highaffin
receptor
nogo
receptor
infect
neuron
murin
central
nervou
system
konopkaanstadt
et
al
moreov
spheroid
cultur
glioma
cell
reovirus
enter
via
rout
distinct
rout
use
monolay
cultur
cell
wherea
monolay
cultur
glioma
cell
wildtyp
reoviru
reli
jama
bind
entri
jama
express
dispens
cell
grown
multicellular
spheroid
dautzenberg
et
al
could
attribut
action
extracellular
factor
incub
wildtyp
reovirus
condit
medium
spheroid
cultur
convert
virus
particl
infecti
also
monolay
cultur
jamadefici
cell
presum
acidifi
environ
high
amount
cathepsin
allow
convers
virus
partial
uncoat
infecti
subvir
particl
isvp
isvp
associ
directli
plasma
membran
penetr
membran
allow
jama
endosomeindepend
entri
cytoplasm
dautzenberg
et
al
mechan
may
contribut
vari
effici
reoviru
transduct
observ
cultur
resect
glioma
cell
van
den
hengel
et
al
data
illustr
monolay
cultur
extrem
use
studi
biolog
paramet
oncolyt
virus
care
taken
extrapol
data
predict
perform
oncolyt
virus
tumor
mani
year
princip
mode
action
oncolyt
virus
believ
direct
lytic
effect
tumor
cell
base
concept
adopt
dutch
research
numer
strategi
develop
enhanc
viru
entri
replic
spread
cytolyt
activ
describ
strategi
also
includ
inhibit
antivir
immun
respons
prevent
rapid
viral
clearanc
loss
oncolyt
activ
cotreat
cyclophosphamid
lamfer
et
al
oncolyt
viru
therapi
immun
system
foe
friend
protect
host
contain
viral
infect
may
also
frustrat
effici
infect
replic
spread
therapeut
virus
therebi
limit
antitumor
efficaci
moreov
becom
increasingli
appar
oncolyt
virus
also
capabl
initi
immun
reaction
lead
develop
tumorspecif
tcell
respons
fact
terminolog
form
cancer
treatment
shift
oncolyt
viru
therapi
viroimmunotherapi
immunovirotherapi
canceroncolyt
vaccin
treatment
first
evid
aspect
oncolyt
efficaci
came
field
herp
simplex
viru
hsv
therapi
preclin
studi
perform
laboratori
fraser
philadelphia
pa
martuza
washington
dc
use
oncolyt
virus
respect
demonstr
system
antitumor
immun
upon
treatment
immunecompet
anim
associ
elev
cytotox
lymphocyt
ctl
activ
specif
tumor
cell
todo
et
al
fraser
nakano
et
al
comparison
differ
hsvbase
oncolyt
virus
breast
cancer
model
reveal
variabl
level
viru
replic
clearanc
tumor
howev
therapeut
activ
relat
level
dangerassoci
molecular
pattern
damp
intratumor
antigenpres
cell
circul
antigenspecif
cell
suggest
initi
stage
hsvinduc
activ
antitumor
immun
import
viral
persist
within
tumor
workenh
mossman
studi
antitumor
immun
stimulatori
role
adenovirus
lag
behind
oncolyt
virus
speci
specif
human
adenoviru
henc
consequenti
limit
xenograft
model
immunedefici
mice
moreov
rel
eas
genet
modif
adenovir
genom
facilit
develop
rang
oncolyt
adenovirus
arm
immunestimul
transgen
alemani
strategi
yield
promis
result
intrins
immunestimul
activ
adenoviru
still
remain
fulli
chart
work
telomerasedepend
replicationcompet
adenovirus
demonstr
upon
tumor
cell
infect
danger
signal
molecul
releas
dendrit
cell
dc
produc
ifnc
yield
tumordirect
cytotox
also
inhibit
distant
metastas
endo
et
al
edukulla
et
al
netherland
lamfer
colleagu
demonstr
oncolyt
adenoviru
capabl
elicit
effect
tcellmedi
antitumor
respons
longlast
immun
orthotop
model
glioma
cotreat
dexamethason
complet
abrog
effect
support
role
antitumor
immun
respons
oncolyt
adenoviru
therapi
kleijn
et
al
interestingli
even
absenc
viral
replic
adenoviru
shown
induc
immun
respons
tumor
cell
resid
demonstr
occur
upon
administr
adenoviru
vector
syngen
rat
model
colorect
liver
cancer
geutsken
et
al
anoth
approach
adenoviru
employ
effect
vaccin
vehicl
dctarget
vaccin
murin
melanoma
model
target
melanomaassoci
tumor
antigen
significantli
enhanc
antitumor
efficaci
induct
tumorspecif
cell
hangalapura
et
al
limit
host
rang
much
less
problem
mammalian
orthoreoviru
reovirus
antitumor
efficaci
evalu
immunecompet
anim
model
allow
studi
contribut
immun
system
antitumor
efficaci
smakman
et
al
immun
respons
reoviru
treatment
well
character
number
studi
laboratori
melcher
leed
unit
kingdom
vile
rochest
mn
harrington
london
unit
kingdom
pandha
guildford
unit
kingdom
melanoma
prostat
cancer
ovarian
carcinoma
model
shown
reovirusinduc
tumor
cell
death
lead
cytokin
chemokin
product
display
tumorspecif
immunogen
peptid
dc
dc
produc
rang
cytokin
chemokin
undergo
matur
migrat
tumor
microenviron
along
cell
nk
cell
prestwich
et
al
gujar
et
al
steel
et
al
reoviru
treatment
also
shown
decreas
frequenc
immunesuppress
cell
myeloidderiv
suppressor
cell
regulatori
cell
gujar
et
al
also
clinic
studi
intratumor
intraven
reoviru
administr
signific
tcell
infiltr
reovirusinject
tumor
observ
well
increas
circul
perforingranzym
tcell
number
thirukkumaran
et
al
similar
data
obtain
variou
oncolyt
virus
includ
measl
viru
vaccinia
viru
vesicular
stomat
viru
vsv
parvoviru
newcastl
diseas
viru
altogeth
data
suggest
common
mechan
action
oncolyt
virusinduc
antitumor
immun
respons
initi
intratumor
replic
viru
lead
tumor
cell
lysi
releas
pathogenassoci
molecular
pattern
pamp
eg
viral
protein
nucleic
acid
damp
eg
highmobl
group
protein
uric
acid
guo
et
al
tumorassoci
antigen
taa
immun
cell
recogn
pamp
damp
conserv
receptor
innat
immun
system
known
pattern
recognit
receptor
eg
tolllik
receptor
drive
immedi
innat
immun
respons
lead
product
type
interferon
ifn
guillerm
et
al
sieben
et
al
cytokin
enhanc
express
mhc
class
ii
costimulatori
molecul
moreov
increas
product
addit
cytokin
chemokin
includ
tnfa
rant
observ
diaconu
et
al
donnelli
et
al
kleijn
et
al
antigenpres
cell
take
taa
releas
tumor
cell
effect
induc
antigenspecif
tcell
activ
cytokinedriven
proinflammatori
respons
compromis
immunosuppress
tumor
microenviron
enhanc
express
mhc
well
costimulatori
molecul
involv
antigen
present
far
mechan
involv
virusinduc
cell
kill
receiv
rel
littl
attent
dutch
oncolyt
viru
research
studi
abroad
demonstr
mechan
cell
death
play
essenti
role
elicit
antitumor
immun
understand
mechan
may
contribut
develop
effici
agent
viral
oncolysi
immunotherapi
cell
death
proceed
either
immunogen
cell
death
nonimmunogen
cell
death
tesnier
et
al
green
kroemer
variou
type
cell
death
process
recogn
includ
apoptosi
necrosi
autophag
cell
death
necroptosi
pathogentrigg
pyroptosi
kroemer
levin
labb
saleh
apart
apoptosi
cell
death
process
consid
proinflammatori
immunogen
also
apoptosi
immunogen
form
document
obeid
et
al
boozari
et
al
immunogen
cell
death
provok
releas
taa
conjunct
damp
pamp
molecul
well
inflammatori
cytokin
tang
et
al
togeth
creat
environ
aid
elicit
antitumor
immun
oncolyt
virus
immunogen
cell
death
mechan
describ
hsv
ndv
reoviru
report
induc
apoptot
autophag
cell
death
pathway
variou
tumor
cell
szeberenyi
et
al
stanzial
et
al
colunga
et
al
thirukkumaran
et
al
adenovirusmedi
cell
kill
report
apoptosi
independ
may
associ
autophagi
abou
el
hassan
et
al
ito
et
al
jiang
et
al
measl
viru
shown
induc
apoptot
mechan
syncyti
death
associ
proinflammatori
process
mcdonald
et
al
donnelli
et
al
also
indirect
cell
kill
target
tumor
vasculatur
exampl
contribut
immunogen
tumor
releas
damp
necrot
cell
jing
et
al
breitbach
et
al
clear
antitumor
immun
respons
elicit
oncolyt
virus
contribut
significantli
therapeut
benefit
sever
strategi
enhanc
antitumor
respons
current
investig
oncolyt
virus
genet
engin
express
immunestimulatori
transgen
silenc
immunesuppress
signal
tumor
altern
oncolyt
treatment
combin
convent
immunomodulatori
treatment
boost
anticanc
efficaci
insert
transgen
encod
proinflammatori
cytokin
interleukin
il
granulocytemacrophag
colonystimul
factor
gmcsf
extens
studi
preclin
clinic
studi
vacchelli
et
al
also
insert
tcell
costimulatori
molecul
ligand
ligand
evalu
atherton
lichti
insert
taa
express
cassett
shown
enhanc
antitumor
efficaci
preclin
model
well
dave
et
al
insert
gmcsf
cdna
oncolyt
virus
explor
number
clinic
trial
aka
pexavec
tumorselect
vaccinia
viru
carri
gmcsf
gene
heo
et
al
phase
dose
escal
studi
patient
metastat
solid
tumor
treat
intraven
inject
breitbach
et
al
treatment
well
toler
doserel
antitumor
activ
found
interestingli
level
proinflammatori
cytokin
ifnc
tumor
necrosi
factor
tnf
increas
dosedepend
manner
breitbach
et
al
studi
kim
et
al
function
antitumor
immun
pexavec
administr
assess
rabbit
tumor
model
sera
treat
patient
data
show
antibodymedi
complementdepend
cytotox
adcc
play
import
role
induct
select
antitumor
immun
respons
furthermor
abil
induc
adcc
correl
improv
surviv
treat
patient
anoth
clinic
trial
oncolyt
adenoviru
arm
gmcsf
show
correl
antivir
antitumor
immun
suggest
antivir
immun
capabl
break
tumorassoci
immun
toler
kanerva
et
al
treatment
talimogen
laherparepvec
tvec
formerli
known
oncovex
gmcsf
gmcsfarm
oncolyt
herp
viru
result
clinic
stabl
diseas
treat
patient
phase
studi
hu
et
al
immunolog
analysi
subsequ
phase
ii
studi
demonstr
presenc
local
distant
antitumor
immun
respons
patient
advanc
melanoma
senzer
et
al
kaufman
et
al
although
studi
present
promis
data
combin
oncolyt
virus
gmcsf
actual
therapeut
benefit
need
confirm
larger
clinic
trial
recent
groundbreak
result
immun
checkpoint
blockad
antibodi
ipilimumab
nivolumab
respect
metastat
melanoma
wolchok
et
al
surg
interest
immunotherapeut
approach
cancer
therapi
may
offer
new
combinatori
strategi
viroimmunotherapi
immun
checkpoint
play
import
role
prevent
tissu
damag
activ
cell
contribut
immunesuppress
state
tumor
microenviron
chen
fli
revers
tumorinduc
immun
suppress
either
blockad
immun
checkpoint
activ
costimulatori
molecul
lead
activ
cell
longterm
antitumor
immun
pardol
combin
virotherapi
immunotherapi
theori
provid
effect
virusinduc
tumor
cell
lysi
releas
antigen
costimulatori
agent
effici
enhanc
antitumor
immun
respons
elicit
oncolyt
modal
combin
modal
potenti
overcom
immunosuppress
tumor
cell
enhanc
antitumor
efficaci
oncolyt
virus
combin
blockad
variou
preclin
model
murin
melanoma
model
oncolyt
newcastl
diseas
viru
combin
system
administr
antibodi
zamarin
et
al
result
tumor
reject
format
protect
antitumor
memori
model
periton
mous
mammari
tumor
combin
treatment
recombin
vsv
rvsv
antibodi
result
cure
anim
protect
longterm
memori
respons
wherea
treatment
rvsv
alon
ineffect
gao
et
al
deplet
tcell
subset
abrog
antitumor
efficaci
rvsv
blockad
highlight
import
tcelldepend
mechan
viroimmunotherapi
data
demonstr
combin
oncolyt
virotherapi
immunotherapi
immunecheckpoint
inhibitor
produc
robust
tcellmedi
immun
respons
protect
antitumor
memori
oncolyt
viru
therapi
success
effect
virusinduc
oncolysi
taa
cytokin
danger
signal
releas
probabl
requir
well
co
stimul
cell
approach
oncolyt
viru
therapi
gener
effect
tumor
vaccin
situ
li
et
al
bartlett
et
al
howev
data
clinic
trial
suggest
variabl
respons
oncolyt
viru
treatment
even
patient
bear
similar
tumor
type
grade
becom
evid
intertumor
variabl
respons
given
anticanc
therapi
reflect
underli
epi
genet
heterogen
within
tumor
type
support
notion
treatment
strategi
tailor
specif
molecular
trait
virus
modul
exploit
host
cell
machineri
produc
viral
progeni
induc
cell
death
mutat
alter
underli
pathway
may
influenc
effici
process
inde
alreadi
mark
heterogen
suscept
patientderiv
glioblastoma
stem
cell
cultur
reovirusinduc
cytolysi
demonstr
directli
correl
effici
cell
entri
infect
van
den
hengel
et
al
addit
efficaci
viral
replic
cell
lysi
also
danger
signal
amount
cytokin
chemokin
releas
infect
cell
strongli
influenc
ensu
antitumor
immun
respons
thu
far
limit
data
avail
intertumor
variat
innat
tumor
respons
donnelli
et
al
describ
measl
virusinduc
variabl
cytokin
chemokin
releas
melanoma
cell
line
although
specif
pattern
express
emerg
studi
use
panel
patientderiv
tumor
cell
cultur
tissu
sampl
help
chart
tumorspecif
oncolysi
innat
respons
avail
molecular
data
tumor
approach
may
aid
identifi
molecular
correl
predict
antitumor
efficaci
particular
viru
final
success
mount
antitumor
immun
respons
also
depend
efficaci
antigen
present
tcell
activ
map
express
pattern
immunerel
molecul
patientderiv
tumor
specimen
may
offer
lead
enhanc
tcell
activ
strategi
perpati
basi
includ
oncolyt
virus
arm
immun
stimulatori
transgen
cotreat
immun
checkpoint
inhibitor
togeth
approach
ultim
delin
tumor
profil
predict
optim
oncolyt
viru
optim
immunestimul
strategi
particular
tumor
help
guid
futur
individu
viroimmunotherapi
treatment
ambit
drive
current
oncolyt
viru
research
netherland
abroad
